Our results show that although bFGF is elevated in breast carcinomas compared to normal breast tissue it is not related to microvessel density and it is not an independent predictor of survival in breast cancer patients. Basic FGF may be one of multiple factors that synergise with other growth factors such as VEGF to enhance angiogenesis.
We studied the frequency of microvessels in T3 NO MO colorectal carcinomas from patients with widely different survival times. Microvessels (<50 nm diameter) were enhanced by immunostaining with antibody to factor VHI-related antigen and counted in 40x high-power fields in sections of resected carcinomas from 9 patients who died of disease in 24 months or less (short-term survivors) and 13 who had no evidence of disease at 109 months or longer (longterm survivors). The means of the 10 highest counts for each case were compared between the long-and short-term survivor groups. The mean ± SD microvessel count was 25.4 ± 6.5 for the short-term survivors and 30.3 ± 6.4 for the long-term survivors. Median counts There is ample evidence that angiogenesis is a major factor supporting the growth of tumors.1,2 Morphologic studies enumerating microvessels in tissue sections have shown an association between higher frequency of tumor microvessels and poor patient survival, increased risk for recurrence, and metastasis in tumors from many sites, including breast, lung, genitourinary tract, and skin.3 , 4 These studies suggested that microvessel counts performed on tissue sections of tumors may be of prognostic value in the workup of patients with cancer.Although stage at presentation is the most important prognostic factor for colorectal carcinoma, 5-year survival for stage II (T3) colorectal carcinomas ranges from 60% to 80%.5 It would be advantageous to have additional prognostic information to further refine the definition of stage II and to help predict whether patients will have good or poor clinical outcomes. Findings in previous studies of tumor vessels in his- were 27.2 and 29.4, respectively. The distribution of microvessel counts was skewed toward higher counts in the long-term survivors. There was no correlation between microvessel counts and tumor site, size, or grade; lymphovascular invasion; or the presence of a mucinous component. Although there was a trend toward a higher frequency of microvessels in patients with longer survival, it is unlikely that microvessel count is an independent prognostic indicator for patients with T3 NO M0 colorectal carcinoma because there is only a small difference in microvessel frequency between patients with widely different survival times. (Key words: Microvessel counts; Colorectal carcinoma) Am J Clin Pathol 1998;109:733-737. tologic sections of resected colorectal carcinomas agree that microvessel counts may be prognostically useful, but they do not agree on what a high or low count should indicate. Some studies showed an association between high microvascular count and shortterm survival [6][7][8] and between a high microvascular count and tumor recurrence. 8,9 However, Lindmark et al 10 found higher microvessel counts in patients with longer survivals.The aim of this study was to compare microvessel counts in T3 NO M0 colorectal carcinomas from patients with long-term (>109 months) and shortterm (<24 months) survival to determine whether microvessel counts differ in pat...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.